|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Core Alzheimer's Disease (AD) biomarkers are the cerebrospinal fluid (CSF) proteins amyloid β42 and β40, and the tau proteins, total and phosphorylated.
|
31437430 |
2019 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Alzheimer's Disease (AD) is an age-dependent neurodegenerative disorder, the most common type of dementia that is clinically characterized by the presence of beta-amyloid (Aβ) extracellularly and intraneuronal tau protein tangles that eventually leads to the onset of memory and cognition impairment, development of psychiatric symptoms and behavioral disorders that affect basic daily activities.
|
31642777 |
2019 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
In particular Schizandrin-mediated effects on expression of glycogen synthase kinase (GSK)-3β, protein kinase B (Akt) and Tau protein, known to be altered in AD were determined.
|
31739764 |
2019 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Neurofibrillary tangles of hyperphosphorylated tau protein (p-tau) are a key pathological feature of Alzheimer's disease (AD).
|
31394202 |
2019 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
AD leads to progressive loss of cognition, and pathological hallmarks of AD include aggregates of amyloid-β peptides extracellularly and MAPT (microtubule associated protein tau) intracellularly.
|
30922179 |
2019 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
While Alzheimer's Disease (AD) treatment strategies have largely focussed on beta-amyloid and tau protein pathologies, the synapse itself may also be a critical endpoint to consider regarding disease modification.
|
31396031 |
2019 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Glycogen synthase kinase-3β (GSK-3β) is a key enzyme in hyperphosphorylation of tau proteins and is a promising therapeutic target in Alzheimer's disease (AD).
|
29944335 |
2019 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Although genetic factors surrounding the production and clearance of amyloid-β and phosphorylated tau proteins are known to be responsible for a subset of early-onset AD cases, they do not explain the pathogenesis of the far more prevalent sporadic late-onset variant of the disease.
|
31600762 |
2019 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
The cytoplasmic microtubule associated protein tau and alpha-synuclein (αS) are found in an assembled state in Alzheimer's disease and Parkinson's disease, respectively.
|
31214163 |
2019 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our results imply that linear polyubiquitination follows K48-linked polyubiquitination in abnormally accumulated tau proteins in Alzheimer's disease, and imply involvement in its neurodegeneration.
|
30885635 |
2019 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
For the accumulation of intracellular hyperphosphorylated tau proteins is a major pathogenic factor in neurodegeneration of AD, the distributional pattern of tau could highlight the affected brain regions associated with specific cognitive deficits.
|
31724513 |
2019 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Alzheimer's disease (AD) is one of such diseases whose origin is enigmatic, having an impact on later stage of life drastically due to irreparable damage of cognition, characterised by the presence of neurotoxic amyloid-beta (Aβ) plaques and hyper phosphorylated Tau protein as fibrillary tangles.
|
30101703 |
2019 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Recent research has highlighted synergistic interactions between aggregated amyloid-β (Aβ) and tau proteins in AD, but the molecular details of how these interactions drive AD pathology remain elusive and speculative.
|
31627745 |
2019 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Studies with the tracers specific for tau protein showed that patients with AD with elevated tau deposits had higher cognitive performances compared with patients with similar levels of tau deposits.
|
30784080 |
2019 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Alzheimer's disease (AD) is a progressive neurodegenerative disease that was histopathologically characterized in the brain by the presence of extracellular senile plaques made of amyloid β peptides and intracellular neurofibrillary tangles composed of hyperphosphorylated Tau protein.
|
31169189 |
2019 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
The two basic pathological aspects of AD are related to amyloid beta (Aβ) peptides and tau proteins.
|
30968345 |
2019 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
The pathological features of Alzheimer's disease (AD) include senile plaques induced by amyloid-β (Aβ) protein deposits, neurofibrillary tangles formed by aggregates of hyperphosphorylated tau proteins and neuronal cell loss in specific position within the brain.
|
31417361 |
2019 |
|
Alzheimer's Disease
|
0.700 |
PosttranslationalModification
|
disease |
BEFREE |
It is considered that β-amyloid deposition, abnormal phosphorylation of tau protein, and neurofibrillary tangles are the basic pathological changes of AD.
|
30530893 |
2019 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Alzheimer's disease (AD) is a devastating neurodegenerative disorder characterized by the presence of extracellular senile plaques primarily composed of Aβ peptides and intracellular neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau proteins.
|
31248178 |
2019 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Pathologically altered tau protein is a common denominator of neurodegenerative disorders including Alzheimer's disease (AD) and other tauopathies.
|
31391090 |
2019 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
The microtubule-associated protein tau is an attractive therapeutic target for the treatment of Alzheimer's disease and related tauopathies as its aggregation strongly correlates with disease progression and is considered a key mediator of neuronal toxicity.
|
31239479 |
2019 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Accumulation of misfolded and aggregated forms of tau protein in the brain is a neuropathological hallmark of tauopathies, such as Alzheimer's disease and frontotemporal lobar degeneration.
|
31667556 |
2019 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
The prominent pathological consequences of Alzheimer's disease (AD) are the misfolding and mis-sorting of two cellular proteins, amyloid-β and microtubule-associated protein Tau.
|
31093687 |
2019 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Tau protein is found to be aggregated and hyperphosphorylated (p-tau) in many neurologic disorders, including Parkinson disease (PD) and related parkinsonisms, Alzheimer disease, traumatic brain injury, and even in normal aging.
|
31085590 |
2019 |
|
Alzheimer's Disease
|
0.700 |
PosttranslationalModification
|
disease |
BEFREE |
β-amyloid (Aβ) deposition, neurofibrillary tangles induced by phosphorylation of tau protein, and neuronal apoptosis are pathological hallmarks of Alzheimer's disease (AD).
|
31231206 |
2019 |